Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced an agreement with Nanna Therapeutics (Nanna).

Under the terms of the agreement, Ubiquigent will provide Nanna with access to its deubiquitylase (DUB) focused drug discovery platform to support the development of novel therapeutics for human disease targets selected by Nanna.

The DUB enzymes regulate ubiquitination in the ubiquitin-proteasome system (UPS). Dysregulation of DUB activity is implicated in many human diseases, highlighting their importance and promise for developing novel therapeutics.

Ubiquigent is the partner chosen by many leading industry and academic organisations for their drug discovery programmes in the fields of protein degradation, stabilisation and cellular signalling.  Ubiquigent has an established specialised drug discovery platform and long-standing expertise in the exploitation of the DUBs for therapeutic benefit.

The platform can be applied to support the development of DUB inhibitors, DUB-targeting PROTACs, and DUBTACs across any therapeutic area.

We are delighted to enter this latest agreement and look forward to supporting the team at Nanna Therapeutics. Our platform was established to support those seeking to modulate DUB activity for therapeutic benefit and has been used by a long list of global partners which we are very pleased to add Nanna Therapeutics to.”

Jason Mundin, CEO of Ubiquigent

To learn more about Ubiquigent’s discovery and development platform, please visit https://www.ubiquigent.com/platform

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Ubiquigent Limited. (2024, March 11). Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics. News-Medical. Retrieved on November 21, 2024 from https://www.news-medical.net/news/20240311/Ubiquigent-enters-agreement-with-Astellas-subsidiary-Nanna-Therapeutics.aspx.

  • MLA

    Ubiquigent Limited. "Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics". News-Medical. 21 November 2024. <https://www.news-medical.net/news/20240311/Ubiquigent-enters-agreement-with-Astellas-subsidiary-Nanna-Therapeutics.aspx>.

  • Chicago

    Ubiquigent Limited. "Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics". News-Medical. https://www.news-medical.net/news/20240311/Ubiquigent-enters-agreement-with-Astellas-subsidiary-Nanna-Therapeutics.aspx. (accessed November 21, 2024).

  • Harvard

    Ubiquigent Limited. 2024. Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics. News-Medical, viewed 21 November 2024, https://www.news-medical.net/news/20240311/Ubiquigent-enters-agreement-with-Astellas-subsidiary-Nanna-Therapeutics.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Alleo and Ubiquigent enter AI-driven strategic partnership to accelerate DUB-focused drug discovery